ACHE and Alzheimer disease: Most of the ChE inhibitors (ChEIs) employed in the therapy of AD blocks both AChE and BuChE; however, experimental studies highlighted that compounds selectively targeting AChE have a higher therapeutic index as BuChE inhibition can cause adverse effects to the peripheral nervous system (Li et al., 2016).